accessibility menu, dialog, popup

UserName
Viewing profile as user:

Organic lithium salts

Organic compound that contains one or more lithium ions bonded by ionic bonds. Salts are products of acid-base reactions.

Filtered Search Results

Products from some of our suppliers do not display in filtered search results. Please clear all filters to see these products.

Narrow Results

Narrow Results

category

brands

  • (5)

special interests

  • (5)

Search Within Results
Keyword Search:
1 – 5 of 5 results
1

Medchemexpress LLC Mevalonic acid lithium salt | 2618458-93-6 | 98.0% | 154.09 | 10 MG
SDP

Mevalonic acid (MVA) lithium salt is a precursor substance of the mevalonate pathway, which is essential for cell growth and proliferation. It is effective in inhibiting Simvastatin-induced decrease in C2C12 cell viability in vitro. Mevalonic acid lithium salt can be used in studies of myopathy and heart failure.

  • Precursor substance of the mevalonate pathway.
  • Essential for cell growth and proliferation.
  • Effective in inhibiting Simvastatin-induced decrease in C2C12 cell viability in vitro.
  • Can be used in studies of myopathy and heart failure.
  • High purity.
  • Available in solid and solution forms.
  • Supported by multiple publications citing its use.

ENCOMPASS_PREFERRED
2

Medchemexpress LLC Lith-O-Asp | 881179-02-8 | 98.0% | 491.66 | 100 MG
SDP

Lith-O-Asp is a sialyltransferase (ST) inhibitor with IC50s of 12-37 μM. It inhibits the activities of ST3Gal I, ST3Gal III, and ST6GalI, decreasing the expression of cell surface α-2,3- and α-2,6-sialylated antigens.

  • Inhibits sialyltransferase (ST) activities with IC50 values ranging from 12 to 37 μM.
  • Decreases the activity of both α-2,3- and α-2,6-sialyltransferases.
  • Inhibits the transfer of sialic acids to targeted glycoproteins.
  • Shows no apparent growth inhibition effect toward different cancer cell lines at tested doses.
  • Leads to fewer lung metastases in treated mice.
  • Decreases average tumor nodules per mouse in vivo.

ENCOMPASS_PREFERRED
3

Medchemexpress LLC Cholan-24-oic acid, 3-[(2S)-2-amino-3-carboxy-1-oxopropoxy]-, (3α,5β)- | 881179-02-8 | 98.0% | 491.66 | 25 MG
SDP

Lith-O-Asp is a sialyltransferase (ST) inhibitor, with IC50 values ranging from 12-37 μM against ST3Gal I, ST3Gal III, and ST6GalI. It inhibits α-2,3- and α-2,6-sialyltransferases, decreasing sialic acid transfer to targeted glycoproteins. Research shows potential in suppressing cancer angiogenesis and metastasis, with treated mice exhibiting fewer lung metastases in a 4T1-Luc breast cancer model.

  • Sialyltransferase (ST) inhibitor
  • IC50 values of 12-37 μM against ST3Gal I, ST3Gal III, and ST6GalI
  • No apparent growth inhibition effect on different cancer cell lines at tested doses (10, 30, and 60 μM)
  • Decreases expression of cell surface α-2,3- and α-2,6-sialylated antigens
  • Suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways in vivo

ENCOMPASS_PREFERRED
4

Medchemexpress LLC Lith-O-Asp | 881179-02-8 | MFCD31692386 | 98.0% | 491.66 g/mol | C28H45NO6 | 5 MG
SDP

Lith-O-Asp is a small-molecule sialyltransferase (ST) inhibitor reported to inhibit ST activity with IC50 values of 12-37 μM. It is provided as a purified research reagent in solid form for biochemical and cell-based studies; not for human therapeutic use.

  • Inhibits sialyltransferase with IC50 12-37 μM.
  • High purity (98.0%).
  • Molecular formula C28H45NO6 and molecular weight 491.66 g/mol.
  • Supplied as a solid in milligram quantities suitable for screening and assays.
  • Intended for research use only; not for therapeutic applications.
  • CAS number 881179-02-8 for unambiguous identification.

ENCOMPASS_PREFERRED
5

Medchemexpress LLC Cholan-24-oic acid, 3-[(2S)-2-amino-3-carboxy-1-oxopropoxy]-, (3α,5β)- | 881179-02-8 | 98.0% | 491.66 | 10 MG
SDP

Lith-O-Asp is a sialyltransferase (ST) inhibitor with IC50 values ranging from 12-37 μM. It has been shown to decrease the activity of both α-2,3- and α-2,6-sialyltransferases, thereby inhibiting the transfer of sialic acids to targeted glycoproteins. Research indicates that Lith-O-Asp may suppress cancer angiogenesis and metastasis pathways, as demonstrated by fewer lung metastases in treated mice compared to controls.

  • Sialyltransferase (ST) inhibitor.
  • Inhibits the activities of ST3Gal I, ST3Gal III, and ST6GalI.
  • Decreases expression of cell surface α-2,3- and α-2,6-sialylated antigens.
  • Suppresses cancer angiogenesis and metastasis pathways.

ENCOMPASS_PREFERRED